Hemophilia Gene Therapy — Readying for Clinical Care: Webinar Series

Hemophilia Gene Therapy—Readying for Clinical Care

CME Information

ACCREDITED PROVIDER
This activity is provided by The France Foundation and produced in collaboration with the International Society on Thrombosis and Haemostasis.
Activity Title: Gene Therapy in Hemophilia Self-Assessment Module
Topic: Gene Therapy in Hemophilia
Accreditation Type: AMA PRA Category 1 Credit(s)
Release Date: October 20, 2022
Expiration Date: October 19, 2023
Estimated Time to Complete Activity: 75 minutes

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity
  2. Review the activity objectives and CME/CE information
  3. Complete the CME/CE activity
  4. Complete this CME/CE evaluation/attestation form: https://surveys.francefoundation.com/s3/9153-ISTH-Hemophilia-Gene-Therapy-Readying-for-Clinical-Care-Enduring-Evaluation

    This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and their views on future educational needs
  5. If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download

TECHNICAL REQUIREMENTS

This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox, and Safari browsers.

Additionally, this site and its activities are best viewed using the latest Operating System for your device.

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL